[Editorial] Hepatitis C: global ambition, national realities
Last week, new surveillance data released by the US Centers for Disease Control and Prevention (CDC), report that US hepatitis C virus (HCV)-associated deaths reached a record high—19 659 in 2014. Around 3·5 million people are currently living with HCV in the USA. The cost of direct-acting antivirals (DAAs), the curative drug class of choice in new WHO guidelines, is prohibitive, with some US insurers covering only severe cases. WHO has added most new DAAs to its model list of essential medicines.